An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia

Exclusion Criteria

• •Severe vomiting and difficulty in taking oral medication or ingestion of drugs after oral administration
• •Suspected or confirmed active systemic infection other than COVID-19 pneumonia
• •Pregnant or lactating women
• •Patients with mental disorders
• •Patients with severe liver damage
• •Patients who are treated with small molecule drugs such as Nirmatrelvir Tablets/Ritonavir Tablets(co-packaged)
• •Patients who are treated with RNA-dependent RNA polymerase (RDRP) inhibitors (Junshipharma VV116, Ascletis Pharma Inc. Asc10, Kexing biopharm Shen26, and Molnupiravir).